MetaVia Inc. (NASDAQ:MTVA – Free Report) – HC Wainwright issued their Q4 2024 EPS estimates for shares of MetaVia in a research report issued to clients and investors on Monday, December 30th. HC Wainwright analyst E. Arce anticipates that the company will post earnings per share of ($0.74) for the quarter. HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for MetaVia’s current full-year earnings is ($3.91) per share. HC Wainwright also issued estimates for MetaVia’s FY2025 earnings at ($2.61) EPS and FY2026 earnings at ($2.73) EPS.
MetaVia Stock Up 3.9 %
NASDAQ MTVA opened at $2.11 on Wednesday. MetaVia has a twelve month low of $1.51 and a twelve month high of $6.75.
MetaVia Company Profile
MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.
Further Reading
- Five stocks we like better than MetaVia
- 3 REITs to Buy and Hold for the Long Term
- 3 Legacy Tech Companies Reemerging as AI LeadersÂ
- 3 Warren Buffett Stocks to Buy Now
- Analysts’ Favorite Cybersecurity Stocks: 3 Top Picks
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Analysts Are Bullish: 3 Tech Giants With Upgraded Price Targets
Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.
